newsYale University and AI Therapeutics will collaborate on a Phase…
28 July 2020 | By Victoria Rees (European Pharmaceutical Review)
Yale University and AI Therapeutics will collaborate on a Phase II trial to study LAM-002A as a COVID-19 treatment for newly diagnosed patients.